Olmesartan Restores <i>LMNA</i> Function in Haploinsufficient Cardiomyocytes
In silico screening followed by in vitro validation with induced pluripotent stem cell-derived models can be an efficient approach to identifying repositionable therapies for monogenic cardiomyopathies.
Authors
- Eric J. Kort (ORCID: https://orcid.org/0000-0002-9966-7483)
- Gema Mondéjar‐Parreño (ORCID: https://orcid.org/0000-0001-9514-8961)
- Nazish Sayed (ORCID: https://orcid.org/0000-0002-8229-721X)
- Joseph C. Wu (ORCID: https://orcid.org/0000-0002-6068-8041)
- Stefan Jovinge (ORCID: https://orcid.org/0000-0002-8446-0228)
- Sean M. Wu (ORCID: https://orcid.org/0000-0002-0000-3821)
- Emily Eugster
- Chun Liu (ORCID: https://orcid.org/0000-0002-8242-3896)
- J.-G. Forsberg
Institutions
- Grand Rapids Community College (US)
- Van Andel Institute (US)
- Spectrum Health (US)
- Cardiovascular Institute of the South (US)
- Helen DeVos Children's Hospital (US)
- Skåne University Hospital (SE)
- Center for Vascular Biology Research (US)
- Stanford University (US)
Publication Details
- Journal
- Circulation
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1161/circulationaha.121.058621
- Citations
- 3
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.16